Estrogen is one of the major sex steroid hormones that is produced from the human ovary, and its actions are established to be a receptormediated process. Despite the demonstration of estrogen receptor (ER) expression, little is known regarding the regulation of ER in the human ovary. In the present study we investigated the expression and hormonal regulation of ER␣ and ER␤ in human granulosa-luteal cells (hGLCs). Using RT-PCR amplification, both ER␣ and ER␤ messenger ribonucleic acid (mRNA) were detected from hGLCs. Northern blot analysis revealed that ER␣ is expressed at a relatively lower level than ER␤. Basal expression studies indicated that ER␣ mRNA levels remain unchanged, whereas ER␤ mRNA levels increased with time in culture in vitro, suggesting that ER␤ is likely to play a dynamic role in mediating estrogen action in hGLCs.
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The regulation of ER␣ and ER␤ expression by hCG was examined. hCG treatment (10 IU/mL) significantly attenuated the ER␣ (45%; P Ͻ 0.01) and ER␤ (40%; P Ͻ 0.01) mRNA levels. The hCG-induced decrease in ER␣ and ER␤ expression was mimicked by 8-bromo-cAMP (1 mmol/L) and forskolin (10 mol/L) treatment. Additional studies using a specific protein kinase A (PKA) inhibitor (adenosine 3Ј,5Ј-cyclic monophosphorothioate, Rp-isomer, triethylammonium salt) and an adenylate cyclase inhibitor (SQ 22536) further implicated the involvement of the cAMP/PKA signaling pathway in hCG action in these cells. The hCG-induced decrease in ER␣ and ER␤ mRNA levels was prevented in the presence of these inhibitors. Next, the effect of GnRH on ER expression was studied. Sixty-eight percent (P Ͻ 0.001) and 60% (P Ͻ 0.001) decreases in ER␣ and ER␤ mRNA levels, respectively, were observed after treatment with 0.1 mol/L GnRH agonist (GnRHa). Pretreatment of the cells with a protein kinase C (PKC) inhibitor (GF109203X) completely reversed the GnRHainduced down-regulation of ER␣ and ER␤ expression, suggesting the involvement of PKC in GnRH signal transduction in hGLCs. In agreement with the semiquantitative RT-PCR results, Western blot analysis detected a decrease in ER␣ and ER␤ proteins levels in hGLCs after treatment with hCG (10 IU/mL), GnRH (0.1 mol/L), 8-bromocAMP (1 mmol/L), forskolin (10 mol/L), or phorbol 12-myristate 13 acetate (10 mol/L). Functionally, we demonstrated an inhibition of progesterone production in hGLCs in vitro by 17␤-estradiol, and this inhibitory effect was eliminated by pretreatment of 10 IU/mL hCG or 0.1 mol/L GnRHa for 24 h before 17␤-estradiol administration.
In summary, we observed a differential expression of ER␣ and ER␤ mRNA in hGLCs in vitro. The demonstration of hCG-and GnRHainduced down-regulation of ER␣ and ER␤ gene expression suggests that hCG and GnRH may contribute to the control of granulosa-luteal cell function. Furthermore, our data suggest that the effects of hCG and GnRH on ER␣ and ER␤ expression in hGLCs are mediated in part by activation of PKA and PKC signaling pathways, respectively. I T IS WELL documented that estrogen plays an important role in regulating reproductive function. Until recently, the classical estrogen receptor (now known as ER␣) was thought to be the only form of nuclear receptor that binds estradiol and mediates its hormonal effects. However, the recent cloning of second form of estrogen receptor (ER␤) in rat (1), mouse (2) , and human (3) has opened a new era in the study of estrogen signaling. Studies using in situ hybridization and immunohistochemistry have revealed that ER␣ is localized primarily in the ovarian stromal cells and thecal cells of the rat (4), whereas ER␤ is concentrated predominately in the granulosa cells of small, developing, and preovulatory follicles in rat and bovine ovary (4 -6) . The development of ER␣ knockout (␣ERKO) mice (7) and ER␤ knockout (␤ERKO) mice (8) provides an excellent model to study ER␣-and ER␤-mediated events. Female ␣ERKO mice are anovulatory and infertile even in the presence of significant levels of ER␤ expression (7, 9) , whereas ovarian follicular development and ovulation are partially compromised in ␤ERKO mice (8) . The observation that the ␣ERKO ovary contains primary and secondary follicles implicates a role for ER␤ in early follicular development. On the other hand, final follicle maturation is hampered in the ␣ERKO, suggesting an interaction between ER␣ and ER␤ in controlling the later phases of folliculogenesis. Although both ER␣ and ER␤ have been detected in the rat corpus luteum (CL) (5, 10, 11) , the precise role of estrogen and its receptor in the CL remains unclear.
Several studies have suggested that estrogen may regulate ovarian function in humans, including modulation of steroidogenesis from human granulosa-luteal cells (hGLCs) (12) , inhibition of 3␤-hydroxysteroid dehydrogenase in luteal cells (13) , and inhibition of luteal progesterone produc-tion (13, 14) . These observations suggest the presence of functionally active ERs within the human ovary. The recent demonstration of ER␣ and ER␤ messenger ribonucleic acid (mRNA) in the human CL and hGLCs further corroborate this idea (15, 16) . Despite the expression of ER␣ and ER␤ in the human ovary, little is known about the hormonal regulation of ER␣ and ER␤ in the human ovary. The present study was designed to investigate the regulation of ER␣ and ER␤, at the mRNA and protein levels, by hCG and GnRH in hGLCs.
Materials and Methods hGLC culture
The use of hGLCs was approved by the clinical screening committee for research and other studies involving human subjects of the University of British Columbia. GLCs were harvested in conjunction with oocyte collection in the University of British Columbia's in vitro fertilization program. Throughout the precollection period, follicular development was monitored using estradiol assays and ultrasonography. After pituitary down-regulation with GnRH analog (Synarel, Syntex, Montreal, Canada), follicular development was stimulated with hMG (75 IU FSH and 75 IU LH, Humegon ,Organon, Scarborough, Canada; or 75 IU FSH, Fertinorm Serono, Oakville, Canada). Final maturation was induced with hCG (10,000 IU; Serono) when two or more follicles had reached diameters of 16 -18 mm. Follicles were harvested 36 h later using a transvaginal approach. Human GLCs from the follicular fluid were prepared and cultured as described previously (17) . The isolated granulosa cells were cultured at a density of 2 ϫ 10 5 cells/mL in medium 199 (Life Technologies, Inc., Burlington, Canada) supplemented with 10% FBS, 10 U/mL penicillin, and 10 g/mL streptomycin (Life Technologies, Inc.) in a 37 C humidified environment with 5% CO 2 . 
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RNA isolation and RT-PCR amplification
hGLC total RNA was prepared as previously described (18) . The RNA concentration was determined based on the absorbance at 260 nm, and its integrity was confirmed by agarose-formaldehyde gel electrophoresis. One microgram of total RNA isolated from hGLCs was reverse transcribed into first strand complementary DNA (cDNA) in a total volume of 15 L using First Strand cDNA Synthesis Kit (Pharmacia Biotech, Morgan, Canada), following the manufacturer's suggested procedure. PCR primers specific for ER␣ (forward, 5Ј-ATGACCATGAC-CCTCAACACCAA-3Ј; reverse, 5Ј-CTTGGCAGATTCCATAGCCAT-AC-3Ј) and ER␤ (forward, 5Ј-TACAGCATTCCCAGCAATGTCAC-3Ј; reverse, 5Ј-GAAGTGAGCATCCCTCTTTGAAC-3Ј) were designed based on the published sequence of human ER␣ and ER␤ cDNAs, respectively (3, 19) . The cDNA was amplified in a 50 L PCR reaction containing 2.5 U Taq polymerase (Life Technologies, Inc.) and its buffer, 1.5 mmol/L MgCl 2 , 10 mmol/L of each deoxy-NTP, and 25 pmol of the respective specific primers. Thirty-five cycles of amplification were carried out by denaturing at 94 C for 1 min, annealing for 1 min at 55 C, extension for 90 s at 72 C, and a final extension for 15 min at 72 C. Several controls were performed to determine the accuracy of the PCR. First, PCR was performed in the absence of cDNA to examine the crosscontamination of sample. Second, PCR for ␤-actin (sense, 5Ј-GGACCT-GACTGACTACCTAATGAA-3Ј; antisense, 5Ј-TGATCCACATCTGCT-GGAAGGTGG-3Ј) was run in parallel to rule out the possibility of RNA degradation and to normalize the levels of ER␣ and ER␤ PCR products. Finally, as all primer pairs used span at least one intron, the sizes of the predicted PCR products ruled out the presence of contaminating genomic DNA in the RNA sample.
The amplified ER␣ and ER␤ PCR products were cloned into PCR II vector using the TA Cloning Kit (Invitrogen, San Diego, CA), and the putative ER␣ and ER␤ cDNAs were sequenced by the dideoxy nucleotide chain termination method using the T7 DNA Polymerase Sequencing Kit (Amersham Pharmacia Biotech, Morgan, Canada). Semiquantitative PCR for ER␣ and ER␤ mRNA levels were performed with 30 and 27 cycles of amplifications, respectively. The expression levels PCR for ER␣ and ER␤ in hGLCs were normalized against ␤-actin levels.
Northern and Southern blot analyses
Five to 40 g total RNA isolated from hGLCs were resolved by formaldehyde denaturing agarose gel electrophoresis and prepared for Northern blot analysis of ER␣ and ER␤ mRNA. Radiolabeled ER␣ and ER␤ probes were prepared using the Random Labeling Kit (Life Technologies, Inc.). The membrane was prehybridized and hybridized in standard hybridization solution [50% formamide, 5 ϫ SSPE (0.09 m NaCl, 5 mm NaH 2 PO 4 , 5 mm EDTA [pH 7.4]), 5 ϫ Denhardt's solution, 0.5% SDS, and 100 g/mL denatured herring sperm DNA] at 42 C. The membrane was washed at high stringency conditions (0.1 ϫ SSPE and 0.1% SDS at 65 C for 10 min) and exposed to Kodak Omat x-ray film (Eastman Kodak Co., Rochester, NY).
For quantitation of human ER␣ and ER␤ mRNA levels, PCR products were separated by agarose gel electrophoresis and transferred to nylon membranes, which were hybridized with digoxigenin-labeled ER␣ and ER␤ cDNA probes (Roche Molecular Biochemicals, Laval, Canada). After washing at high stringency conditions, the membranes were exposed to Kodak Omat x-ray film. The radioautograms were then scanned and quantified with Scion Image-Released Beta 3b (Scion Corp., Bethesda, MD).
Pharmacological treatments
Pharmacological reagents, including d-Ala 6 -GnRH, which is a GnRH agonist (GnRHa), hCG, forskolin, phorbol 12-myristate 13 acetate (TPA), and 17␤-estradiol (E 2 ) were purchased from Sigma-Aldrich Corp. (Oakville, Ontario, Canada). The protein kinase C (PKC) inhibitor (PKCI), bisindolymaleimide I (GF109203X); the protein kinase A (PKA) inhibitor (PKAI), adenosine 3Ј,5Ј-cyclic monophosphorothioate Rp-isomer triethylammonium salt; and the adenylate cyclase inhibitor (ACI), SQ 22536 were obtained from Calbiochem (La Jolla, CA). In experiments in which the effects of GnRHa, hCG, forskolin, and TPA on ER␣ and ER␤ expression were studied, the cells were treated for 24 h before total RNA or total cellular protein isolation. To study the PKA and PKC signaling pathway, hGLCs were pretreated with 20 mol/L PKAI, 0.5 mmol/L ACI, or 10 mol/L PKCI 30 min before the addition of hCG or GnRHa.
Western blot analysis
For Western blot analysis, hGLCs were incubated in 75 L cell lysis buffer RIPA [containing 1 ϫ PBS (pH 7.4), 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 g/mL phenylmethylsulfonylfluoride, 30 g/mL aprotinin, and 10 g/mL leupeptin] for 15 min on ice. The cell lysates were centrifuged to remove cellular debris. The supernatant was used in Western blot analysis. The protein concentration in the cell lysates was determined using a modified Bradford assay (Bio-Rad Laboratories, Inc., Richmond, CA). An aliquot (35 g) was taken from the total cell lysates and subjected to SDS-PAGE under reducing conditions. The stacking gels contained 5% (wt/vol) acrylamide, and the separating gels were composed of 8% (wt/vol) acrylamide. The proteins were electrophoretically transferred from the gels onto nitrocellulose paper (Hybond-C, Amersham Pharmacia Biotech). The nitrocellulose blots were blocked with 5% (wt/vol) nonfat milk in Tris buffer saline, containing 20 mmol/L Tris-Cl (pH 8.0), 140 mmol/L NaCl, and 0.05% (wt/vol) Tween-20. The membranes were then probed with a mouse monoclonal antibody (1:2000) directed against human ER␣ (Santa Cruz Biotechnology, Inc., Santa Cruz, CA; catalogue no. sc-8002) or goat polyclonal antibody (1:1000) against human ER␤ (Santa Cruz Biotechnology, Inc., catalogue no. sc-6822). All antibody incubations and washes were performed in Tris-buffered saline with 0.05% Tween-20. The Amersham Pharmacia Biotech enhanced chemiluminescence system (ECL) was used for detection. Membranes were visualized by exposure to Kodak X-Omat film. The radioautograms were then scanned and quantified with Scion Image-Released Beta 3b (Scion Corp.).
Progesterone RIAs
Human GCs were seeded at a density of 5 ϫ 10 5 cells in 35-mm dishes. On days 3 and 6 in culture, hGLCs were washed twice with medium and treated with 1 nmol/L, 0.1 m 17␤-estradiol, or vehicle in triplicate for 24 h before collection of sample medium. To study the effect of 17␤-estradiol on progesterone secretion after down-regulation of ERs by hCG and GnRHa, hGLCs on day 5 were pretreated with 10 IU/mL hCG, 0.1 mol/L GnRHa, or vehicle for 24 h. The cells were then washed twice with medium and further incubated in the presence of 0.1 mol/L 17␤-estradiol for an additional 24 h. The medium was removed and stored at Ϫ20 C before being assayed for progesterone content. The cells were lysed with 100 L RIPA, and the total protein concentration was used to standardize the progesterone secretion. The RIA for progesterone was preformed as previously described (20) . The standard curve and samples were assayed in triplicate. Inter-and intraassay coefficients of variation were less then 10%.
Data analysis
Data are shown as the mean Ϯ se from four independent experiments from four patients. The data were analyzed by one-way ANOVA followed by Dunnett's or Tukey's multiple comparison test using SPSS computer software (version 9.0, SPSS, Inc., Chicago, IL). Data were considered statistically significant different from controls when P Ͻ 0.05.
Results
Expression of ER␣ and ER␤ mRNA in cultured hGLCs
The expression of ER␣ and ER␤ mRNA in cultured human granulosa-luteal cells was examined by RT-PCR. Using PCR primers designed from the published ER␣ and ER␤ cDNA sequences, the expected 540-bp product for ER␣ and the 279-bp product for ER␤ were observed by agarose gel electrophoresis and ethidium bromide staining (Fig. 1A) . Sequence analysis of the PCR products revealed that they were identical to the published human ER␣ and ER␤ sequences, respectively (3, 19) . In addition, Northern blot analysis revealed a 6.5-kb ER␣ transcript, from 40 g total RNA isolated from hGLCs, only after a long exposure period (10 days). The same blot was stripped and rehybridized with ER␤ probe. Multiple transcripts for ER␤ ranging from 1.35-9.5 kb were observed after 2 days of exposure (Fig. 1B) , and these signals could be detected from as low as 15 g total RNA (data not shown). These results confirm the expression of ER␣ and ER␤ in hGLCs and suggest that a higher level of ER␤ mRNA is expressed in these cells.
Changes in ER␣ and ER␤ mRNA levels in hGLCs in vitro
Due to the low levels of endogenous ER␣ mRNA in hGLCs and the limited availability of cells for Northern blot analysis, RT-PCR amplification was employed to quantify the relative ER␣ and ER␤ mRNA levels in subsequent experiments. PCR optimization showed a linear amplification of ER␣ or ER␤ cDNA up to 35 and 30 cycles of amplification, respectively ( Fig. 2A) . Similarly, a linear amplification for ␤-actin was obtained from 15-25 cycles (data not shown). As a result, 30 and 27 cycles of amplification for ER␣ and ER␤ cDNA, respectively, were performed. In addition, 18 cycles for ␤-actin were performed to standardize the ER expression.
To determine the changes in ER␣ and ER␤ mRNA levels in vitro, the isolated hGLCs were cultured for 1, 4, 7, and 10 days before RNA extraction and RT-PCR analysis. The relative mRNA levels of ER␣ and ER␤ were expressed as the percent change with respect to the day 1 mRNA levels. As shown in Fig. 2B , no statistically significant change in ER␣ mRNA levels was observed between days of culture. In contrast, ER␤ mRNA levels gradually increased in vitro. Thirty percent (P Ͻ 0.05), 60% (P Ͻ 0.01), and 58% (P Ͻ 0.01) increases in ER␤ mRNA levels were observed on days 4, 7, and 10 of culture, respectively.
Regulation of ER␣ and ER␤ mRNA levels by hCG and PKA pathway in hGLCs
As hCG is a major physiological regulator of ovarian function (21), we examined the effect of hCG in modulating ER␣ and ER␤ expression in hGLCs. As shown in Fig. 3 , no significant change in ER␣ and ER␤ mRNA levels was observed in day 1 cultured hGLCs after hCG treatment. The levels of ER␣ and ER␤ mRNA were decreased to 55% (P Ͻ 0.01 vs. control) and 60% (P Ͻ 0.01 vs. control), respectively, in response to a 24-h treatment with 10 IU/mL hCG on day 7 of culture. These inhibitory effects were also observed in day 10 cultures. Further studies using hGLCs on day 7 in culture revealed a dose-and time-dependent decrease in ER␣ and ER␤ mRNA levels after hCG treatment (Fig. 4) . A significant decrease in ER mRNA levels was observed when cells were treated with 1 and 10 IU/mL hCG for 24 h (Fig. 4A) . Prolonged treatment with 10 IU/mL hCG (48 h) did not further decrease the mRNA levels of ERs compared to the effect of 24-h treatment (Fig. 4B) . To investigate the potential role of the hCG-stimulated PKA signaling pathway in regulating ER␣ and ER␤ gene expression, hGLCs on day 7 in culture were treated with 1 mmol/L 8-bromo-cAMP and 10 mol/L forskolin for 24 h. As shown in Fig. 5 , a significant decrease (P Ͻ 0.01) in both ER␣ and ER␤ mRNA was observed after hCG ( and ER␤ was abolished in the presence of PKAI or ACI, whereas PKCI or ACI alone did not significantly affect the expression of ERs (Fig. 6 ). These data suggest that activation of the PKA pathway by hCG results in a down-regulation of ER gene expression in hGLCs.
Regulation of ER␣ and ER␤ mRNA levels by GnRH and PKC pathway in hGLCs
The expression of GnRH and its receptor and the demonstration of direct effects of GnRH on progesterone production in hGLCs have suggested an autocrine/paracrine role for GnRH in the ovary (17, 22) . To investigate the ability of GnRH to alter ER␣ and ER␤ gene expression, hGLCs on day 1, 7, or 10 in culture were treated with 0.1 mol/L GnRHa for 24 h. ER␣ and ER␤ mRNA levels were examined by semiquantitative RT-PCR. As shown in Fig. 7 , GnRHa failed to affect ER␣ and ER␤ mRNA levels in day 1 and 10 cultured hGLCs, but caused 68% (P Ͻ 0.001 vs. control) and 60% (P Ͻ 0.001 vs. control) decreases in ER␣ and ER␤ mRNA, respectively, in day 7 cultured hGLCs. These results suggest a temporal regulation of ER␣ and ER␤ mRNA by GnRHa in hGLCs. Further studies using day 7 cultured hGLCs revealed a dose-and time-dependent regulation of ER␣ and ER␤ mRNA levels (Fig. 8) . A significant decrease (P Ͻ 0.01) in ER␣ and ER␤ mRNA levels was observed when cells were treated with 0.1 mol/L GnRHa for 24 h (Fig. 8A) . No further decrease in ER mRNA levels was observed when the GnRHa concentration was increased to 1 mol/L. The decreases in ER␣ and ER␤ mRNA levels were observed after 12-and 24-h treatment with 0.1 mol/L GnRHa (Fig. 8B) . It has been well documented that binding of GnRH receptor to its ligands activates the PKC pathway. In the human ovary, however, the second messenger pathway involved in GnRH action remains unclear. To determine the potential role of the PKC signaling pathway on GnRH action in regulating ER␣ and ER␤ mRNA in hGLCs, a specific PKC inhibitor, GF109203X, was used. Day 7 cultures of hGLCs were treated with vehicle, 0.1 mol/L GnRHa, 1 mol/L PKC inhibitor, and PKC inhibitor plus GnRHa for 24 h (Fig. 9 ). PKC inhibitor alone had no effect on ER␣ and ER␤ gene expression. However, GnRHa-mediated down-regulation of ER gene expression was inhibited in the presence of PKCI (Fig. 9) . The effect of GnRHa-mediated down-regulation of ER␣ and ER␤ mRNA was mimicked by TPA treatment (data not shown), further implicating a role of the PKC pathway in regulating ER gene expression.
Effects of GnRH, TPA, hCG, 8-bromo-cAMP, and forskolin on ER␣ and ER␤ protein levels
Western blot analysis of hGLCs using antibodies directed against ER␣ and ER␤, respectively, revealed a 68-kDa ER␣ and a 55-kDa ER␤ protein species in all of the cellular extracts (Fig. 10) . In agreement with the results from RT-PCR analysis, 45% (P Ͻ 0.01) and 40% (P Ͻ 0.01) decreases in ER␣ and ER␤ protein levels, respectively, were observed after 0.1 mol/L GnRHa treatment. Similarly, hCG treatment (10 IU/ mL) resulted in a significant decrease in ER␣ and ER␤ protein levels to 60% (P Ͻ 0.01) and 57% (P Ͻ 0.01) of control levels. These reductions in ER␣ and ER␤ protein levels were also observed after TPA, 8-bromo-cAMP, and forskolin treatments.
Effects of hCG and GnRHa pretreatment on 17␤-estradiolmediated progesterone production
By the use of day 4 and day 7 hGLCs in culture, the effect of 17␤-estradiol on progesterone production was studied. Thirty percent (P Ͻ 0.01) and 34% (P Ͻ 0.01) decreases in progesterone secretion from day 4 hGLCs were observed after 1 nmol/L and 0.1 mol/L 17␤-estradiol treatments, respectively (Fig. 11A) . Similarly, 40% (P Ͻ 0.01) and 56% (P Ͻ 0.01) decreases in progesterone secretion were observed in day 7 hGLC in culture after 1 nmol/L and 0.1 mol/L 17␤-estradiol treatments, respectively (Fig. 11A ). This inhibitory effect could be blocked by the cotreatment of tamoxifen (data not shown), suggesting that it was an ER-mediated process. The effect of down-regulating ER expression on the E 2 -mediated decrease in progesterone secretion was examined in hGLCs on day 7 of culture. Pretreatment of hGLCs with 10 IU/mL hCG or 0.1 mol/L GnRHa for 24 h before the addition of 0.1 mol/L 17␤-estradiol eliminated the E 2 -induced decrease in progesterone secretion (Fig. 11B) . This inhibition was shown to be specific, as hCG-and GnRHapretreated hGLCs retained the ability to produce progesterone when stimulated by 1 mol/L forskolin (Fig. 11B) .
Discussion
The presence of ER in the ovary, especially in the human, is controversial. Several reports have suggested that ER was not expressed in granulosa cells and CL. For example, an immunohistochemical study showed no specific staining for ER in the human CL (23) . ER mRNA was not detected by RT-PCR in hGLCs (24) or granulosa cells or CL of the baboon (25) . However, others have reported the identification of ER in hGLCs cells and human CL immunologically (26, 27) . Recent studies have demonstrated the expression of ER␣ and ER␤ mRNA in the human ovary (15, 16, 28, 29) . The present study, using RT-PCR and Northern blot analysis, further supported the idea that ER␣ and ER␤ are expressed in hGLCs. However, there appears to be a quantitative difference in the expression of ER␣ vs. ER␤ in the human ovary. By the use of Northern blotting analysis, the ER␣ transcript was only detected with 40 g total RNA isolated from hGLCs, whereas ER␤ can be detected with as little as 15 g total RNA. These results suggest that the expression of ER␣ is at a relatively lower level compared with that of ER␤ in hGLCs. Similar results observed in rat ovarian RNA by Northern blot analysis further support the differential expression of ERs in the ovary (30) . Immunohistochemical studies have shown that ER␤ is the primary ER subtype expressed in rat and bovine ovaries, particularly in granulosa cells, whereas ER␣ was mainly in the germinal epithelium, interstitial cells, and thecal cells of rat ovary (4) . These findings may explain the failure of several studies (23) (24) (25) to detect ER mRNA and protein in granulosa cells by PCR and antibody directed against the ER␣ subclass. Interestingly, others have reported comparable expression of human ER␣ and ER␤ mRNA levels by Northern blot analysis and ribonuclease protection assay in normal human ovaries (15, 31) .
Competitive RT-PCR from human CL revealed similar levels of ER␣ and ER␤ mRNA expression during the luteal phase (16) . One possible explanation is that in these studies using human ovarian tissues, the results could be confounded by other cell types, such as thecal cells, which may express higher levels of ER. This possibility is supported by the differential spatial expression of ER observed in the rat ovary (4) . In the present study we also found that ER␣ and ER␤ mRNA displayed different temporal patterns of expression depending on the day of culture. The expression of ER␤ mRNA levels appears to increase significantly with spontaneous luteinization in vitro. In contrast, ER␣ expression did not change substantially throughout in vitro culture. These data suggest that ER␤, more so than ER␣, plays a dynamic role in regulating CL function in the human.
Gonadotropins are the major regulators of steroidogenesis in the human ovary (32, 33) . As a first attempt to investigate the hormonal regulation of ER expression, we examined the effect of hCG on ER␣ and ER␤ mRNA levels in hGLCs. No significant change in either ER␣ or ER␤ mRNA levels was observed on day 1 of culture. As the granulosa-luteal cells were retrieved from in vitro fertilization patients after exposure to high doses of GnRHa and hCG in vivo, it is possible that the hCG/LH receptor was already down-regulated, which may explain the lack of responsiveness on day 1 in culture. A similar lag period has been observed for the hCG effect on the expression of several other genes in primary cultures of hGLCs (34 -36) . In day 7 cultured hGLCs, hCG produced a time-and concentration-dependent downregulation of both ER␣ and ER␤ mRNA levels. This downregulation was mimicked by 8-bromo-cAMP and forskolin treatments, suggesting that the effect of hCG is mediated via the activation of the PKA pathway. Similar results have been reported in the rat, where hCG treatment of granulosa cells induced a down-regulation of ER␤ mRNA, and this effect was mimicked by 8-bromo-cAMP and TPA treatment (30) . The participation of PKA signaling pathway in regulating human ER gene expression in hGLCs was further examined pharmacologically using a specific PKAI and ACI. The hCGinduced down-regulation of ER␣ and ER␤ expression was abolished in the presence of PKAI or ACI. These results strongly support the idea that down-regulation of ER␣ and ER␤ gene expression in the ovary by hCG was mediated through the PKA signaling pathway.
GnRH is primarily recognized for its role in the regulation of LH and FSH release from the pituitary gland. However, GnRH is also thought to be a potential paracrine/autocrine regulator in the gonads (17, 22, 37) . GnRH and its agonists have been shown to exert various effects on ovarian function (17, 22, (37) (38) (39) , and the expression of both GnRH and its receptor in cultured hGLCs (17) further corroborates a putative role for GnRH as an intraovarian hormone. The present study demonstrated that GnRH was able to down-regulate both ER␣ and ER␤ mRNA in hGLCs. In the rat ovary it is well established that the signal transduction pathway for GnRHR is primarily through activation of phospholipase C (40) . It has been shown that TPA significantly down-regulates the expression of ER␤ in rat granulosa cells (30) and ER␣ in a human mammary adenocarcinoma MCF-7 cell (41). In the human ovary, the second messenger pathway(s) involved in GnRH action remains unclear. We have shown that GnRHmediated down-regulation of ER␣ and ER␤ mRNA levels was inhibited in the presence of a PKC inhibitor and was mimicked by TPA administration. These results strongly implicate the activation of the PKC pathway by GnRH in the human ovary and the involvement of the PKC pathway in regulating the expression of ERs in hGLCs.
Although the role of estrogen in human ovarian function in the luteal phase remains unclear, several studies have indicated that estrogen could be an intraovarian regulator of luteolysis (42) . This is supported by the observation that high concentrations of estrogen significantly inhibited luteal steroidogenesis (12) . Administration of tamoxifen from day 18 of the menstrual cycle to the onset of menstruation resulted in a significant prolongation of the luteal phase and an elevation of progesterone levels in human (43) . Similar results were observed in the present study; E 2 treatment resulted in a significant decrease in progesterone secretion from the hGLCs in vitro, which could be block by the coadministration of tamoxifen. Furthermore, hCG and GnRHa pretreatment abolished the E 2 -induced decrease in progesterone secretion, suggesting that the regulation of ER expression by hCG and GnRHa was physiologically important.
Estrogen produced by the primate CL may cause luteolysis (44) by increasing PGF 2␣ levels in the ovary (45) . In the rat and guinea pig, estradiol was found to stimulate the synthesis of PGF2 ␣ (46, 47) . Estradiol has been shown to increase the activity of phospholipase A2 (48) and increase the expression (49) of PG synthase, which control the production of PGF 2␣ . A possible paracrine interaction of estradiol, oxytocin, and PGF 2␣ within the primate ovary may promote luteolysis (50) . It is possible that a similar mechanism exists in the human ovary. It has been demonstrated that estrogen induces PGF 2␣ and oxytocin production and oxytocin receptor expression in various human tissues (51) (52) (53) . Increasing ER␣ and ER␤ levels in the human CL may lead to increased susceptibility to the luteolytic effect of estrogen. On the other hand, down-regulation of ER subtypes in the mid-or late luteal phase may prevent the regression of hGLCs or the CL. Thus, regulation of ER␣ and ER␤ by LH/hCG and GnRH may be important to the function of hGLCs and/or CL.
In summary, we observed a differential temporal expression of ER␣ and ER␤ mRNA in hGLCs in vitro. The demonstration of hCG-and GnRHa-induced down-regulation of ER␣ and ER␤ gene expression suggests a role for these hormones, which may contribute to the control of hGLC and/or CL function. Furthermore, our results indicate that the downregulation of ER␣ and ER␤ by hCG and GnRH in hGLCs is mediated by activation of the PKA and PKC signaling pathways, respectively.
